Independent Advisor Alliance’s Neurocrine Biosciences NBIX Stock Holding History

Independent Advisor Alliance’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,996	Closed	-$212K	–	550
2022 Q3	$212K	Sell	1,996 -398	-17%	-$40.4K	0.01%	569
2022 Q2	$233K	Sell	2,394 -394	-14%	-$36.4K	0.01%	540
2022 Q1	$261K	Sell	2,788 -353	-11%	-$29.9K	0.01%	534
2021 Q4	$268K	Sell	3,141 -505	-14%	-$46.5K	0.01%	550
2021 Q3	$350K	Sell	3,646 -574	-14%	-$54.2K	0.02%	451
2021 Q2	$411K	Buy	4,220 +16	+0.4%	+$1.53K	0.02%	435
2021 Q1	$409K	Buy	4,204 +6	+0.1%	+$629	0.02%	411
2020 Q4	$402K	Buy	4,198 +35	+0.8%	+$3.38K	0.03%	387
2020 Q3	$400K	Buy	4,163 +941	+29%	+$109K	0.03%	336
2020 Q2	$393K	Buy	+3,222	New	+$356K	0.04%	316

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Independent Advisor Alliance's NBIX Position: Q4 2022 in Review

Independent Advisor Alliance sold out of Neurocrine Biosciences (NBIX) in Q4 2022, closing a stake of 1,996 shares — an estimated $212K sold.

Independent Advisor Alliance first reported a position in NBIX in Q2 2020 and held it in 10 quarters. The position peaked at $411K in Q2 2021. 529 funds tracked by Wall St. Rank hold NBIX as of Q4 2022.

Independent Advisor Alliance reported no remaining Neurocrine Biosciences position as of Q4 2022 after selling out during the quarter.
Independent Advisor Alliance sold 1,996 Neurocrine Biosciences shares in Q4 2022, an estimated $212K.
Independent Advisor Alliance first reported a position in Neurocrine Biosciences in Q2 2020 and held it in 10 quarters.
Independent Advisor Alliance's Neurocrine Biosciences position peaked at $411K in Q2 2021.
529 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2022.

Based on Independent Advisor Alliance's 13F filing for Q4 2022, filed 13 Feb 2023.